Brookline Capital Markets Starts NLS Pharmaceutics (NLSP) at Buy, Following Strategic Clinical Update

March 12, 2021 10:39 AM EST Send to a Friend
Brookline Capital Markets analyst Kumaraguru Raja initiates coverage on NLS Pharmaceutics (NASDAQ: NLSP) with a Buy rating and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login